Drug intelligence / Profile preview

RMX-VH-PIB

Development stage: Unknown
Lead developer: Radiomedix
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

RMX-VH-PIB is a radio-theranostic agent being co-developed by Vect-Horus and RadioMedix. It is designed to treat glioblastoma (GBM) and other tumors, such as pancreatic ductal adenocarcinoma, that overexpress the Low-Density Lipoprotein Receptor (LDLR). The drug utilizes Vect-Horus's VECTrans® technology to facilitate its passage across the blood-brain barrier and enhance tumor targeting.

Targets

LDLR (Low-density lipoprotein receptor)

Beyond the preview

Go deeper on RMX-VH-PIB.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMX-VH-PIB.

Explore the full profile